Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer.

Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec; 3(12):1629-40.

View in: PubMed

subject areas

Administration, Oral
Animals
Antineoplastic Agents
Cell Proliferation
Dose-Response Relationship, Drug
Drug Design
Female
High-Throughput Screening Assays
Humans
Inhibitory Concentration 50
Injections, Intravenous
Male
MCF-7 Cells
Mice
Mice, Inbred BALB C
Mice, Inbred NOD
Mice, SCID
Microfilament Proteins
Molecular Structure
Molecular Targeted Therapy
Naphthyridines
Neoplasms
NIH 3T3 Cells
Phosphorylation
Proteasome Endopeptidase Complex
Protein Kinase Inhibitors
RNA Interference
Small Molecule Libraries
src Homology Domains
Structure-Activity Relationship
Time Factors
Transfection
Tumor Burden
Xenograft Model Antitumor Assays

authors with profiles

Yusuke Nakamura